V114
Biological
Merck Sharp & Dohme Corporation
Total Payments
$55.9M
Transactions
16,070
Doctors
128
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $12.5M | 4,203 | 13 |
| 2019 | $28.3M | 7,811 | 73 |
| 2018 | $12.2M | 3,024 | 55 |
| 2017 | $2.8M | 1,032 | 23 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55.5M | 14,797 | 99.3% |
| Consulting Fee | $226,422 | 150 | 0.4% |
| Travel and Lodging | $117,044 | 463 | 0.2% |
| Food and Beverage | $30,722 | 659 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12.00 | 1 | 0.0% |
Payments by Type
Research
$55.5M
14,797 transactions
General
$374,200
1,273 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED | Merck Sharp & Dohme Corporation | $11.8M | 1 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU | Merck Sharp & Dohme Corporation | $7.4M | 0 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. | Merck Sharp & Dohme Corporation | $6.4M | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION | Merck Sharp & Dohme Corporation | $5.3M | 0 |
| A Phase II, Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants | Merck Sharp & Dohme Corporation | $4.4M | 0 |
| Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE | Merck Sharp & Dohme Corporation | $3.9M | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK | Merck Sharp & Dohme Corporation | $3.2M | 1 |
| AOM etiology and pneumococcal serotype distribution | Merck Sharp & Dohme Corporation | $2.9M | 0 |
| Hospitalized pneumococcal community acquired pneumonia in adults - US | Merck Sharp & Dohme Corporation | $2.3M | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 One Year Later in Healthy Adults 50 Years of Age or Older PNEU-PATH | Merck Sharp & Dohme Corporation | $2.2M | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | Merck Sharp & Dohme Corporation | $2.2M | 0 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Eight Weeks Later in Adults Infected with HIV | Merck Sharp & Dohme Corporation | $744,248 | 0 |
| TAP Study CO2 | Merck Sharp & Dohme Corporation | $616,124 | 0 |
| A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant PNEU-STEM | Merck Sharp & Dohme Corporation | $552,413 | 0 |
| A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants | Merck Sharp & Dohme Corporation | $405,046 | 0 |
| Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE | Merck Sharp & Dohme Corporation | $331,242 | 0 |
| Pediatric Carriage Study - Emory | Merck Sharp & Dohme Corporation | $310,302 | 0 |
| A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, andImmunogenicity of V114 in Healthy Adults and Infants | Merck Sharp & Dohme Corporation | $172,626 | 0 |
| Hospitalized pneumococcal community acquired pneumonia in adults and pediatrics - US | Merck Sharp & Dohme Corporation | $110,769 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Active ComparatorcontrolledStudy to Evaluate the Safety, Tolerability, and Immunogenicity of V114 inChildren with Sickle Cell Disease PNEU-SICKLE | Merck Sharp & Dohme Corporation | $102,820 | 0 |
Top Doctors Receiving Payments for V114
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $55.5M | 14,796 |
| , M.D | Internal Medicine | Rochester, MN | $108,305 | 42 |
| , M.D | General Practice | Trujillo Alto, PR | $66,213 | 26 |
| , M.D | Pediatrics | Rochester, MN | $19,250 | 25 |
| , MD | Clinical & Laboratory Immunology | Seattle, WA | $18,006 | 21 |
| , M.D | Infectious Disease | Baltimore, MD | $14,297 | 20 |
| , MD | Infectious Disease | Nashville, TN | $12,750 | 11 |
| , M.D | Medical Oncology | Baltimore, MD | $6,188 | 8 |
| , MD | Internal Medicine | Boston, MA | $6,056 | 7 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $6,000 | 2 |
| , M.D | Infectious Disease | Rochester, MN | $5,738 | 7 |
| , M.D., PH.D | Pediatrics | Philadelphia, PA | $5,100 | 2 |
| , MD | Pediatric Hematology-Oncology | Cincinnati, OH | $4,500 | 1 |
| Kathleen Mullane | Infectious Disease | Burr Ridge, IL | $4,275 | 2 |
| , MD | Pediatrics | Kingsport, TN | $3,861 | 31 |
| , MD | Medical Oncology | New York, NY | $3,500 | 2 |
| , M.D | Pediatric Infectious Diseases | Omaha, NE | $3,235 | 25 |
| , M.D | Pediatrics | Rio Piedras, PR | $3,087 | 23 |
| , M.D | Pediatrics | Lincoln, NE | $3,050 | 22 |
| , MD | Pediatrics | Birmingham, AL | $2,923 | 19 |
| , M.D | Pediatrics | Lincoln, NE | $2,809 | 18 |
| , M.D | Pediatrics | San Diego, CA | $2,791 | 1 |
| , M.D | Pediatrics | Layton, UT | $2,652 | 17 |
| , MD | Pediatrics | Colorado Springs, CO | $2,572 | 20 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $2,500 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $55.9M
- Total Doctors 128
- Transactions 16,070
About V114
V114 is a biological associated with $55.9M in payments to 128 healthcare providers, recorded across 16,070 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $12.5M was paid across 4,203 transactions to 13 doctors.
The most common payment nature for V114 is "Unspecified" ($55.5M, 99.3% of total).
V114 is associated with 20 research studies, including "A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED" ($11.8M).